Clinical Trials Directory

Trials / Unknown

UnknownNCT03817164

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

Multicenter, Randomized, Double-Blind, Sham-Controlled, Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
110 (actual)
Sponsor
Thync Global, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a 16-week, prospective, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate psoriasis treated with ANM. Psoriasis severity and stress levels will be measured at Weeks 0, 2, 8, 12, and 16.

Conditions

Interventions

TypeNameDescription
DEVICEAutonomic Nerve Modulation - ActiveThync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
DEVICEAutonomic Nerve Modulation - ControlThync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.

Timeline

Start date
2018-10-02
Primary completion
2019-10-30
Completion
2019-10-30
First posted
2019-01-25
Last updated
2019-07-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03817164. Inclusion in this directory is not an endorsement.